Craig A Erickson1, Balmiki Ray2, Bryan Maloney2, Logan K Wink1, Katherine Bowers1, Tori L Schaefer1, Christopher J McDougle3, Deborah K Sokol2, Debomoy K Lahiri4. 1. Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 2. Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN, USA. 3. Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 4. Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: dlahiri@iupui.edu.
Abstract
BACKGROUND: Understanding of the pathophysiology of autism spectrum disorder (ASD) remains limited. Brain overgrowth has been hypothesized to be associated with the development of ASD. A derivative of amyloid-β precursor protein (APP), secreted APPα (sAPPα), has neuroproliferative effects and has been shown to be elevated in the plasma of persons with ASD compared to control subjects. Reduction in sAPPα holds promise as a novel molecular target of treatment in ASD. Research into the neurochemistry of ASD has repeatedly implicated excessive glutamatergic and deficient GABAergic neurotransmission in the disorder. With this in mind, acamprosate, a novel modulator of glutamate and GABA function, has been studied in ASD. No data is available on the impact of glutamate or GABA modulation on sAPPα function. METHODS: Plasma APP derivative levels pre- and post-treatment with acamprosate were determined in two pilot studies involving youth with idiopathic and fragile X syndrome (FXS)-associated ASD. We additionally compared baseline APP derivative levels between youth with FXS-associated or idiopathic ASD. RESULTS: Acamprosate use was associated with a significant reduction in plasma sAPP(total) and sAPPα levels but no change occurred in Aβ40 or Aβ42 levels in 15 youth with ASD (mean age: 11.1 years). Youth with FXS-associated ASD (n = 12) showed increased sAPPα processing compared to age-, gender- and IQ-match youth with idiopathic ASD (n = 11). CONCLUSIONS: Plasma APP derivative analysis holds promise as a potential biomarker for use in ASD targeted treatment. Reduction in sAPP (total) and sAPPα may be a novel pharmacodynamic property of acamprosate. Future study is required to address limitations of the current study to determine if baseline APP derivative analysis may predict subgroups of persons with idiopathic or FXS-associated ASD who may respond best to acamprosate or to potentially other modulators of glutamate and/or GABA neurotransmission.
BACKGROUND: Understanding of the pathophysiology of autism spectrum disorder (ASD) remains limited. Brain overgrowth has been hypothesized to be associated with the development of ASD. A derivative of amyloid-β precursor protein (APP), secreted APPα (sAPPα), has neuroproliferative effects and has been shown to be elevated in the plasma of persons with ASD compared to control subjects. Reduction in sAPPα holds promise as a novel molecular target of treatment in ASD. Research into the neurochemistry of ASD has repeatedly implicated excessive glutamatergic and deficient GABAergic neurotransmission in the disorder. With this in mind, acamprosate, a novel modulator of glutamate and GABA function, has been studied in ASD. No data is available on the impact of glutamate or GABA modulation on sAPPα function. METHODS: Plasma APP derivative levels pre- and post-treatment with acamprosate were determined in two pilot studies involving youth with idiopathic and fragile X syndrome (FXS)-associated ASD. We additionally compared baseline APP derivative levels between youth with FXS-associated or idiopathic ASD. RESULTS:Acamprosate use was associated with a significant reduction in plasma sAPP(total) and sAPPα levels but no change occurred in Aβ40 or Aβ42 levels in 15 youth with ASD (mean age: 11.1 years). Youth with FXS-associated ASD (n = 12) showed increased sAPPα processing compared to age-, gender- and IQ-match youth with idiopathic ASD (n = 11). CONCLUSIONS: Plasma APP derivative analysis holds promise as a potential biomarker for use in ASD targeted treatment. Reduction in sAPP (total) and sAPPα may be a novel pharmacodynamic property of acamprosate. Future study is required to address limitations of the current study to determine if baseline APP derivative analysis may predict subgroups of persons with idiopathic or FXS-associated ASD who may respond best to acamprosate or to potentially other modulators of glutamate and/or GABA neurotransmission.
Authors: Craig A Erickson; Logan K Wink; Maureen C Early; Elizabeth Stiegelmeyer; Lauren Mathieu-Frasier; Vanessa Patrick; Christopher J McDougle Journal: J Autism Dev Disord Date: 2014-04
Authors: Matthew T Reilly; Ingrid A Lobo; Lindsay M McCracken; Cecilia M Borghese; Diane Gong; Takafumi Horishita; R Adron Harris Journal: Alcohol Clin Exp Res Date: 2008-02 Impact factor: 3.455
Authors: Jerzy Wegiel; Janusz Frackowiak; Bozena Mazur-Kolecka; N Carolyn Schanen; Edwin H Cook; Marian Sigman; W Ted Brown; Izabela Kuchna; Jarek Wegiel; Krzysztof Nowicki; Humi Imaki; Shuang Yong Ma; Abha Chauhan; Ved Chauhan; David L Miller; Pankaj D Mehta; Michael Flory; Ira L Cohen; Eric London; Barry Reisberg; Mony J de Leon; Thomas Wisniewski Journal: PLoS One Date: 2012-05-02 Impact factor: 3.240
Authors: Craig A Erickson; Balmiki Ray; Logan K Wink; Baindu L Bayon; Ernest V Pedapati; Rebecca Shaffer; Tori L Schaefer; Debomoy K Lahiri Journal: J Psychiatr Res Date: 2016-09-09 Impact factor: 4.791
Authors: Sushmitha S Purushotham; Neeharika M N Reddy; Michelle Ninochka D'Souza; Nilpawan Roy Choudhury; Anusa Ganguly; Niharika Gopalakrishna; Ravi Muddashetty; James P Clement Journal: Exp Brain Res Date: 2022-09-05 Impact factor: 2.064